NASDAQ:SCPHScpharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Scpharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.16 -0.01 (-0.14 %) (As of 07/6/2020 04:00 PM ET) Add Compare Share Today's Range$7.15Now: $7.16▼$7.5550-Day Range$7.01MA: $8.04▼$10.8352-Week Range$3.27Now: $7.16▼$11.99Volume74,300 shsAverage Volume105,641 shsMarket Capitalization$150.43 millionP/E RatioN/ADividend YieldN/ABeta0.48 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingScpharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Scpharmaceuticals has a potential upside of 81.6% from its current price of $7.16.Amount of Analyst CoverageScpharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 2.4 Community Rank Outperform VotesScpharmaceuticals has received 138 “outperform” votes. (Add your “outperform” vote.)Underperform VotesScpharmaceuticals has received 144 “underperform” votes. (Add your “underperform” vote.)Community SentimentScpharmaceuticals has received 51.06% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote “Outperform” if you believe SCPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldScpharmaceuticals does not currently pay a dividend.Dividend GrowthScpharmaceuticals does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Scpharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $4,999,994.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 4.07% of the stock of Scpharmaceuticals is held by insiders.Percentage Held by Institutions59.44% of the stock of Scpharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Scpharmaceuticals are expected to decrease in the coming year, from ($1.80) to ($1.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Scpharmaceuticals is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scpharmaceuticals is -4.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScpharmaceuticals has a P/B Ratio of 2.59. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.2Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.91 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCPH Previous Symbol CUSIPN/A CIK1604950 Webwww.scpharma.com Phone617-517-0730Debt Debt-to-Equity Ratio0.36 Current Ratio16.96 Quick Ratio16.96Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book2.59Profitability EPS (Most Recent Fiscal Year)($1.77) Net Income$-33,000,000.00 Net MarginsN/A Return on Equity-55.07% Return on Assets-38.27%Miscellaneous Employees21 Outstanding Shares21,010,000Market Cap$150.43 million Next Earnings Date8/5/2020 (Estimated) OptionableNot Optionable NASDAQ:SCPH Rates by TradingView Receive SCPH News and Ratings via Email Sign-up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions How has Scpharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Scpharmaceuticals' stock was trading at $7.77 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SCPH shares have decreased by 7.9% and is now trading at $7.16. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Scpharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Scpharmaceuticals. When is Scpharmaceuticals' next earnings date? Scpharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Scpharmaceuticals. How were Scpharmaceuticals' earnings last quarter? Scpharmaceuticals Inc (NASDAQ:SCPH) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.19. View Scpharmaceuticals' earnings history. What price target have analysts set for SCPH? 3 brokerages have issued 1-year target prices for Scpharmaceuticals' stock. Their forecasts range from $10.00 to $15.00. On average, they anticipate Scpharmaceuticals' stock price to reach $13.00 in the next year. This suggests a possible upside of 81.6% from the stock's current price. View analysts' price targets for Scpharmaceuticals. Has Scpharmaceuticals been receiving favorable news coverage? News stories about SCPH stock have been trending negative on Monday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Scpharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Scpharmaceuticals. Are investors shorting Scpharmaceuticals? Scpharmaceuticals saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 58,300 shares, an increase of 81.6% from the June 15th total of 32,100 shares. Based on an average daily volume of 110,200 shares, the short-interest ratio is currently 0.5 days. Currently, 0.3% of the shares of the stock are short sold. View Scpharmaceuticals' Current Options Chain. Who are some of Scpharmaceuticals' key competitors? Some companies that are related to Scpharmaceuticals include Collegium Pharmaceutical (COLL), NextCure (NXTC), Corbus Pharmaceuticals (CRBP), Kala Pharmaceuticals (KALA), Crinetics Pharmaceuticals (CRNX), Syros Pharmaceuticals (SYRS), Basilea Pharmaceutica (BPMUF), Neoleukin Therapeutics (NLTX), Legend Biotech (CALT), Syndax Pharmaceuticals (SNDX), Urogen Pharma (URGN), Athersys (ATHX), Mirum Pharmaceuticals (MIRM), Clovis Oncology (CLVS) and Flexion Therapeutics (FLXN). View all competitors. What other stocks do shareholders of Scpharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Scpharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Selecta Biosciences (SELB), Crispr Therapeutics (CRSP), Protalix Biotherapeutics (PLX), TG Therapeutics (TGTX), Clearside Biomedical (CLSD), Exelixis (EXEL), Fate Therapeutics (FATE), ImmunoGen (IMGN) and Melinta Therapeutics (MLNT). Who are Scpharmaceuticals' key executives? Scpharmaceuticals' management team includes the following people: Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)Dr. Pieter Muntendam, Consultant (Age 61)Ms. Rachael Nokes, Principal Accounting OfficerKatherine Taudvin, Director of Corp. Devel. & Investor RelationsDr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs When did Scpharmaceuticals IPO? (SCPH) raised $96 million in an initial public offering (IPO) on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. What is Scpharmaceuticals' stock symbol? Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH." How do I buy shares of Scpharmaceuticals? Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Scpharmaceuticals' stock price today? One share of SCPH stock can currently be purchased for approximately $7.16. How big of a company is Scpharmaceuticals? Scpharmaceuticals has a market capitalization of $150.43 million. The company earns $-33,000,000.00 in net income (profit) each year or ($1.77) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe. What is Scpharmaceuticals' official website? The official website for Scpharmaceuticals is www.scpharma.com. How can I contact Scpharmaceuticals? Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected] This page was last updated on 7/6/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
